Bart N.M. van Berckel

TL;DR: In this paper, the authors investigated the effect of carrying the rs72824905-G allele on disease risk in a total of 53,627 patients with one of seven brain diseases, including AD, frontotemporal dementia (FTD), dementia with Lewy-bodies (DLB), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) by comparing them with in total 149,290 controls using logistic regression models.

TL;DR: It is demonstrated that commonly used neuropsychological tests differ in their ability to capture decline depending on clinical stage within the AD continuum (preclinical to dementia), which implies that stage-specific cognitive endpoints are needed to accurately assess disease progression and increase the chance of successful treatment evaluation in AD.

TL;DR: To determine whether amyloid imaging with the positron emission tomography (PET) agent Pittsburgh compound B (PiB) can detect vascular β‐amyloid (Aβ) in the essentially pure form of cerebralAmyloid angiopathy associated with the Dutch‐type hereditary cerebral Amyloid Angiopathy (D‐CAA) mutation, a PET study is conducted.

TL;DR: Novel MRI and PET techniques improve in-vivo visualization and quantification of the pleomorphic aspects of neuroinflammation, providing a unique insight in its pathogenesis, clinical relevance, and therapy responsiveness in MS.

TL;DR: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) adds (semi‐)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD‐related progression as well as address methodological challenges in amyloids PET.